Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors in Heart Failure

Mechanisms and Clinical Applications: A Machine-Generated Literature Overview

Mukesh Nandave (Hrsg.)

PDF
ca. 171,19
Amazon iTunes Thalia.de Hugendubel Bücher.de ebook.de kobo Osiander Google Books Barnes&Noble bol.com Legimi yourbook.shop Kulturkaufhaus ebooks-center.de
* Affiliatelinks/Werbelinks
Hinweis: Affiliatelinks/Werbelinks
Links auf reinlesen.de sind sogenannte Affiliate-Links. Wenn du auf so einen Affiliate-Link klickst und über diesen Link einkaufst, bekommt reinlesen.de von dem betreffenden Online-Shop oder Anbieter eine Provision. Für dich verändert sich der Preis nicht.

Springer Nature Singapore img Link Publisher

Naturwissenschaften, Medizin, Informatik, Technik / Pharmazie

Beschreibung

The book delves into the development and therapeutic potential of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors for the treatment of diabetes and cardiovascular diseases. It explores their mechanism of action, cardiovascular benefits, and role in primary and secondary protection from renal and cardiovascular diseases. The book also highlights their emerging opportunities in the management of myocardial infarction, diabetic cardiomyopathy, and congestive heart failure. It provides a comprehensive review of preclinical and clinical information on the cardiovascular advantages of SGLT2 inhibitors. Additionally, the book explores selective drugs and their effects on cardiovascular events, mortality, and safety outcomes in individuals with type 2 diabetes.

The book is a valuable resource for researchers, healthcare professionals, and individuals interested in the field of SGLT2 inhibitors and their impact on diabetes and cardiovascular health.

Weitere Titel in dieser Kategorie
Cover Pharmacology
Rumi Michael Leigh
Cover Diuretics
Rumi Michael Leigh
Cover Antibiotics
Rumi Michael Leigh
Cover Adrenoceptors
Martin C. Michel

Kundenbewertungen

Schlagwörter

Congestive heart failure, SGLT2 inhibitors in type 2 diabetes, Mechanisms of SGLT2 inhibitors for cardiovascular benefits, SGLT2 inhibitors in cardiovascular outcomes, Myocardial infarction